NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 04/21/2022 17:43
Last Report Issued 01/19/2015 12:14

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2527U-POS
Patient ID 2527U-POS
Chain 15000136
DOB Not Given
Sex Not Given
Workorder 15000136

Received 01/19/2015

Lab ID 15000136-001
Matrix Urine
Patient Name 2527U-POS
Patient ID 2527U-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2527U Lacosamide, Urine				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Lacosamide	500	mcg/mL	5.0	
Synonym(s): Vimpat®				
Lacosamide is a functionalized amino acid specifically synthesized as an anticonvulsant drug. In addition to being approved for use as an adjunctive therapy treatment of partial-onset seizures it has been investigated as a treatment for diabetic neuropathic pain. Lacosamide can be administered either orally or intravenously. The recommended initial dose is 50 mg/twice a day, up to a maintenance dose of 200 to 400 mg/day.				
Single labeled oral or intravenous lacosamide doses in healthy subjects were eliminated in urine (95%) and feces (< 0.5%) over a 7 day interval. Urinary excretion products included parent drug (40% of the dose) and the pharmacologically inactive O-desmethyllacosamide.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.